Starling Oncology, Inc. Revenue Beats Estimates by $1.11 Million in Q3

The company posted a 14-cent GAAP loss per share and positive adjusted EBITDA of $3.4 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.